STOCK TITAN

Hoth Therapeutics to Attend 2025 BIO International Convention

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Hoth Therapeutics (NASDAQ: HOTH), a clinical-stage biopharmaceutical company, announced that CEO Robb Knie will attend the BIO International Convention in Boston from June 16-19, 2025. The event is recognized as the largest biotechnology convention globally, bringing together approximately 20,000 industry leaders from the biotech ecosystem. The BIO International Convention serves as a significant platform for networking and industry insights in the biotechnology sector.
Hoth Therapeutics (NASDAQ: HOTH), una società biofarmaceutica in fase clinica, ha annunciato che l'Amministratore Delegato Robb Knie parteciperà alla BIO International Convention a Boston dal 16 al 19 giugno 2025. L'evento è riconosciuto come la più grande convention mondiale nel settore biotecnologico, riunendo circa 20.000 leader del settore biotech. La BIO International Convention rappresenta una piattaforma importante per il networking e l'approfondimento delle conoscenze nel campo delle biotecnologie.
Hoth Therapeutics (NASDAQ: HOTH), una compañía biofarmacéutica en etapa clínica, anunció que el CEO Robb Knie asistirá a la Convención Internacional BIO en Boston del 16 al 19 de junio de 2025. El evento es reconocido como la convención de biotecnología más grande del mundo, reuniendo a aproximadamente 20,000 líderes de la industria del ecosistema biotecnológico. La Convención Internacional BIO sirve como una plataforma importante para el networking y el intercambio de conocimientos en el sector biotecnológico.
임상 단계의 바이오제약 회사인 Hoth Therapeutics(NASDAQ: HOTH)는 CEO Robb Knie가 2025년 6월 16일부터 19일까지 보스턴에서 열리는 BIO 국제 컨벤션에 참석할 것이라고 발표했습니다. 이 행사는 전 세계에서 가장 큰 생명공학 컨벤션으로 약 20,000명의 생명공학 업계 리더들이 모이는 자리입니다. BIO 국제 컨벤션은 생명공학 분야에서 네트워킹과 산업 인사이트를 얻을 수 있는 중요한 플랫폼입니다.
Hoth Therapeutics (NASDAQ : HOTH), une société biopharmaceutique en phase clinique, a annoncé que son PDG, Robb Knie, assistera à la Convention internationale BIO à Boston du 16 au 19 juin 2025. Cet événement est reconnu comme la plus grande convention mondiale en biotechnologie, réunissant environ 20 000 leaders de l'industrie du secteur biotechnologique. La Convention internationale BIO constitue une plateforme majeure pour le réseautage et les échanges d'expertise dans le domaine des biotechnologies.
Hoth Therapeutics (NASDAQ: HOTH), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, gab bekannt, dass CEO Robb Knie vom 16. bis 19. Juni 2025 an der BIO International Convention in Boston teilnehmen wird. Die Veranstaltung gilt als die weltweit größte Biotechnologie-Konferenz und bringt etwa 20.000 Branchenführer aus dem Biotech-Ökosystem zusammen. Die BIO International Convention dient als wichtige Plattform für Networking und Brancheninformationen im Biotechnologiesektor.
Positive
  • None.
Negative
  • None.

NEW YORK, June 16, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company, pioneering breakthrough therapies to improve the lives of patients, today announced that Robb Knie, Chief Executive Officer, is scheduled to attend the BIO International Convention, in Boston, MA, June 16-19,2025.

The BIO International Convention is the largest and most comprehensive event for biotechnology, representing the full ecosystem of biotech with 20,000 industry leaders from across the globe.

To learn more about this event visit https://convention.bio.org/bio-2025.

About Hoth Therapeutics, Inc.
Hoth Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative, impactful, and ground-breaking treatments with a goal to improve patient quality of life. We are a catalyst in early-stage pharmaceutical research and development, elevating drugs from the bench to pre-clinical and clinical testing. Utilizing a patient-centric approach, we collaborate and partner with a team of scientists, clinicians, and key opinion leaders to seek out and investigate therapeutics that hold immense potential to create breakthroughs and diversify treatment options. To learn more, please visit https://ir.hoththerapeutics.com/ .

Forward-Looking Statement
This press release includes forward-looking statements based upon Hoth's current expectations, which may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties, and assumptions. These statements concern Hoth's business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain; the timing and costs of clinical trials, and the timing and costs of other expenses; market acceptance of our products; the ultimate impact of any health epidemic, on our business, our clinical trials, our research programs, healthcare systems, or the global economy as a whole; our intellectual property; our reliance on third-party organizations; our competitive position; our industry environment; our anticipated financial and operating results, including anticipated sources of revenues; our assumptions regarding the size of the available market, benefits of our products, product pricing, and timing of product launches; management's expectation with respect to future acquisitions; statements regarding our goals, intentions, plans, and expectations, including the introduction of new products and markets; and our cash needs and financing plans. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. You should not place reliance on these forward-looking statements, which include words such as "could," "believe," "anticipate," "intend," "estimate," "expect," "may," "continue," "predict," "potential," "project" or similar terms, variations of such terms, or the negative of those terms. Although the company believes that the expectations reflected in the forward-looking statements are reasonable, the company cannot guarantee such outcomes. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described in the section titled "Risk Factors" in Hoth's most recent Annual Report on Form 10-K and Hoth's other filings made with the U. S. Securities and Exchange Commission. All such statements speak only as of the date made. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates, and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance, or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events, or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law.

Investor Contact:
LR Advisors LLC 
Email: investorrelations@hoththerapeutics.com
www.hoththerapeutics.com
Phone: (678) 570-6791

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/hoth-therapeutics-to-attend-2025-bio-international-convention-302481742.html

SOURCE Hoth Therapeutics, Inc.

FAQ

When is Hoth Therapeutics (HOTH) attending the 2025 BIO International Convention?

Hoth Therapeutics will attend the BIO International Convention from June 16-19, 2025, in Boston, MA.

Who will represent Hoth Therapeutics (HOTH) at the 2025 BIO International Convention?

Robb Knie, Chief Executive Officer of Hoth Therapeutics, will represent the company at the convention.

What is the BIO International Convention that HOTH is attending?

The BIO International Convention is the largest biotechnology event globally, bringing together about 20,000 industry leaders from across the biotech ecosystem.

Where is the 2025 BIO International Convention being held?

The 2025 BIO International Convention will be held in Boston, Massachusetts.
Hoth Therapeutics Inc

NASDAQ:HOTH

HOTH Rankings

HOTH Latest News

HOTH Stock Data

15.72M
13.14M
0.93%
3.53%
1.32%
Biotechnology
Pharmaceutical Preparations
Link
United States
NEW YORK